Wilkinson Simon, Gomella Leonard G, Smith Joseph A, Brawer Michael K, Dawson Nancy A, Wajsman Zev, Dai Lanting, Chodak Gerald W
Department of Health Studies and Weiss Memorial Hospital, University of Chicago, Illinois, USA.
J Urol. 2002 Dec;168(6):2505-9. doi: 10.1016/S0022-5347(05)64178-X.
Patients with cancer are increasingly incorporating complementary therapies into the overall treatment. We determine the prevalence and patterns of use of complementary therapies among patients with prostate cancer.
Patients attending 6 urology institutions for prostate cancer management completed a self-administered questionnaire on complementary therapy. All men diagnosed with prostate cancer were eligible, regardless of age, stage of disease or treatment.
A total of 1,099 patients returned the questionnaire. The overall response rate was 78.5%. Complementary therapies had previously been or were currently being used by 23.5% (258) and 18.2% (200) of patients, respectively. Higher levels of education and income were associated with greater use of complementary therapy (p <0.002 by logistic regression). Patients with progressive disease or those primarily treated with hormones were most likely to use complementary therapy. Among the patients using complementary therapy 90% believed that it would help them live longer and improve quality of life, 60% believed it would relieve symptoms and 47% expected it to cure disease.
Complementary therapies are used by a large number of patients with prostate cancer, particularly those with progressive disease or who have undergone multiple treatments. Health care providers need to recognize this growing pattern of use of complementary therapy. Among patients who use complementary therapy the perception of benefit is much greater than that supported by scientific data. Future research should aim to unravel the complex psychosocial dynamics that influence the decision to use complementary therapy by men with prostate cancer and to educate patients about the efficacy of such therapies.
癌症患者越来越多地将补充疗法纳入整体治疗中。我们确定前列腺癌患者中补充疗法的使用 prevalence 和模式。
在 6 家泌尿外科机构接受前列腺癌治疗的患者完成了一份关于补充疗法的自填问卷。所有被诊断为前列腺癌的男性均符合条件,无论年龄、疾病 stage 或治疗情况如何。
共有 1099 名患者返回了问卷。总体回复率为 78.5%。分别有 23.5%(258 名)和 18.2%(200 名)的患者以前曾使用或目前正在使用补充疗法。较高的教育水平和收入与更多地使用补充疗法相关(逻辑回归分析 p<0.002)。患有进展性疾病的患者或主要接受激素治疗的患者最有可能使用补充疗法。在使用补充疗法的患者中,90%的人认为它会帮助他们活得更长并提高生活质量,60%的人认为它会缓解症状,47%的人期望它能治愈疾病。
大量前列腺癌患者使用补充疗法,尤其是那些患有进展性疾病或接受过多种治疗的患者。医疗保健提供者需要认识到这种补充疗法使用的增长模式。在使用补充疗法的患者中,对益处的认知远大于科学数据所支持的程度。未来的研究应旨在揭示影响前列腺癌男性使用补充疗法决策的复杂心理社会动态,并教育患者了解此类疗法的疗效。